C. Durán-Rosas , J. Lara-Carmona , K. Hernández-Flores , F.J. Cabrera-Jorge , F. Roesch-Dietlen , M. Amieva-Balmori , H. Vivanco-Cid , S. Santiesteban-González , P. Thomas-Dupont , J.M. Remes-Troche
{"title":"有消化不良症状的受试者中乳糜泻的血清流行率。对墨西哥人口的研究","authors":"C. Durán-Rosas , J. Lara-Carmona , K. Hernández-Flores , F.J. Cabrera-Jorge , F. Roesch-Dietlen , M. Amieva-Balmori , H. Vivanco-Cid , S. Santiesteban-González , P. Thomas-Dupont , J.M. Remes-Troche","doi":"10.1016/j.rgmx.2023.05.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Celiac disease (CD) is an autoimmune enteropathy that develops in genetically susceptible individuals. The typical gastrointestinal manifestation is diarrhea but symptoms of dyspepsia, such as epigastric pain, nausea, or satiety, can sometimes appear. Previous studies have reported that the prevalence of CD in patients with dyspepsia can be as high as 7%. The aim of the present study was to evaluate CD seroprevalence in subjects with dyspeptic symptoms and a control group in a Mexican population.</p></div><div><h3>Material and methods</h3><p>A case-control study was conducted on blood donors that answered the PAGI-SYM questionnaire for dyspepsia and in whom IgA antibodies to tissue transglutaminase 2 (IgA anti-tTG2) and IgG antibodies to deamidated gliadin peptide (IgG anti-DGP) were determined. CD seroprevalence in subjects with dyspeptic symptoms and in asymptomatic subjects was compared.</p></div><div><h3>Results</h3><p>A total of 427 subjects (76.3% men), with a mean patient age of 34 years (range of 18-65 years) were included. Of those participants, 87 (20.3%) had symptoms of dyspepsia (group A) and 340 (79.6%) were asymptomatic (group B). Antibodies were positive in one (1.15%) of the group A subjects (1/87, 95% CI 0.2-6%), whereas they were positive in 4 (1.18%) of the group B subjects (4/340, 95% CI 0.4-2.9%, p = 0.59).</p></div><div><h3>Conclusions</h3><p>CD seroprevalence in the study population with dyspeptic symptoms (1%) was not different from that of the control population. Thus, CD screening in Mexican patients with dyspepsia is not justified.</p></div>","PeriodicalId":51767,"journal":{"name":"Revista de Gastroenterologia de Mexico","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0375090623000563/pdfft?md5=8b6a230f4183b4ee3ac79a0d62df02d3&pid=1-s2.0-S0375090623000563-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Seroprevalencia de enfermedad celíaca en sujetos con síntomas dispépticos. Un estudio en población mexicana\",\"authors\":\"C. Durán-Rosas , J. Lara-Carmona , K. Hernández-Flores , F.J. Cabrera-Jorge , F. Roesch-Dietlen , M. Amieva-Balmori , H. Vivanco-Cid , S. Santiesteban-González , P. Thomas-Dupont , J.M. Remes-Troche\",\"doi\":\"10.1016/j.rgmx.2023.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and aims</h3><p>Celiac disease (CD) is an autoimmune enteropathy that develops in genetically susceptible individuals. The typical gastrointestinal manifestation is diarrhea but symptoms of dyspepsia, such as epigastric pain, nausea, or satiety, can sometimes appear. Previous studies have reported that the prevalence of CD in patients with dyspepsia can be as high as 7%. The aim of the present study was to evaluate CD seroprevalence in subjects with dyspeptic symptoms and a control group in a Mexican population.</p></div><div><h3>Material and methods</h3><p>A case-control study was conducted on blood donors that answered the PAGI-SYM questionnaire for dyspepsia and in whom IgA antibodies to tissue transglutaminase 2 (IgA anti-tTG2) and IgG antibodies to deamidated gliadin peptide (IgG anti-DGP) were determined. CD seroprevalence in subjects with dyspeptic symptoms and in asymptomatic subjects was compared.</p></div><div><h3>Results</h3><p>A total of 427 subjects (76.3% men), with a mean patient age of 34 years (range of 18-65 years) were included. Of those participants, 87 (20.3%) had symptoms of dyspepsia (group A) and 340 (79.6%) were asymptomatic (group B). Antibodies were positive in one (1.15%) of the group A subjects (1/87, 95% CI 0.2-6%), whereas they were positive in 4 (1.18%) of the group B subjects (4/340, 95% CI 0.4-2.9%, p = 0.59).</p></div><div><h3>Conclusions</h3><p>CD seroprevalence in the study population with dyspeptic symptoms (1%) was not different from that of the control population. Thus, CD screening in Mexican patients with dyspepsia is not justified.</p></div>\",\"PeriodicalId\":51767,\"journal\":{\"name\":\"Revista de Gastroenterologia de Mexico\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0375090623000563/pdfft?md5=8b6a230f4183b4ee3ac79a0d62df02d3&pid=1-s2.0-S0375090623000563-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista de Gastroenterologia de Mexico\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0375090623000563\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Gastroenterologia de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0375090623000563","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
引言和目的乳糜泻(CD)是一种自身免疫性肠病,易发于遗传易感人群。典型的胃肠道表现是腹泻,但有时也会出现上腹痛、恶心或饱腹感等消化不良症状。以往的研究报告显示,消化不良患者的 CD 患病率可高达 7%。本研究旨在评估墨西哥人群中消化不良症状受试者和对照组的 CD 血清流行率。材料和方法本研究对回答消化不良 PAGI-SYM 问卷的献血者进行了病例对照研究,并测定了其组织转谷氨酰胺酶 2 的 IgA 抗体(IgA 抗-tTG2)和脱酰胺麦胶蛋白肽的 IgG 抗体(IgG 抗-DGP)。结果 共纳入 427 名受试者(76.3% 为男性),患者平均年龄为 34 岁(18-65 岁不等)。其中 87 人(20.3%)有消化不良症状(A 组),340 人(79.6%)无症状(B 组)。A组受试者中有1人(1.15%)抗体呈阳性(1/87,95% CI 0.2-6%),而B组受试者中有4人(1.18%)抗体呈阳性(4/340,95% CI 0.4-2.9%,P = 0.59)。因此,对墨西哥消化不良患者进行 CD 筛查是不合理的。
Seroprevalencia de enfermedad celíaca en sujetos con síntomas dispépticos. Un estudio en población mexicana
Introduction and aims
Celiac disease (CD) is an autoimmune enteropathy that develops in genetically susceptible individuals. The typical gastrointestinal manifestation is diarrhea but symptoms of dyspepsia, such as epigastric pain, nausea, or satiety, can sometimes appear. Previous studies have reported that the prevalence of CD in patients with dyspepsia can be as high as 7%. The aim of the present study was to evaluate CD seroprevalence in subjects with dyspeptic symptoms and a control group in a Mexican population.
Material and methods
A case-control study was conducted on blood donors that answered the PAGI-SYM questionnaire for dyspepsia and in whom IgA antibodies to tissue transglutaminase 2 (IgA anti-tTG2) and IgG antibodies to deamidated gliadin peptide (IgG anti-DGP) were determined. CD seroprevalence in subjects with dyspeptic symptoms and in asymptomatic subjects was compared.
Results
A total of 427 subjects (76.3% men), with a mean patient age of 34 years (range of 18-65 years) were included. Of those participants, 87 (20.3%) had symptoms of dyspepsia (group A) and 340 (79.6%) were asymptomatic (group B). Antibodies were positive in one (1.15%) of the group A subjects (1/87, 95% CI 0.2-6%), whereas they were positive in 4 (1.18%) of the group B subjects (4/340, 95% CI 0.4-2.9%, p = 0.59).
Conclusions
CD seroprevalence in the study population with dyspeptic symptoms (1%) was not different from that of the control population. Thus, CD screening in Mexican patients with dyspepsia is not justified.
期刊介绍:
La Revista de Gastroenterología de México es el órgano oficial de la Asociación Mexicana de Gastroenterología. Sus espacios están abiertos a los miembros de la Asociación como a todo miembro de la comunidad médica que manifieste interés por utilizar este foro para publicar sus trabajos, cumpliendo con las políticas editoriales que a continuación se mencionan. El objetivo principal de la Revista de Gastroenterología de México, es publicar trabajos originales del amplio campo de la gastroenterología, así como proporcionar información actualizada y relevante para el área de la especialidad y áreas afines. Los trabajos científicos incluyen las áreas de Gastroenterología clínica, endoscópica, quirúrgica y pediátrica.